Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00561197 · ClinicalTrials.gov registry record · Phase 1
An Open-label, Single-center, Phase 1/ 2 Study of Chemoradiotherapy and AT-101 in Patients With Locally Advanced Esophageal or Gastroesophageal Junction Cancer
A Phase 1 study, sponsored by Ascenta Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT00561197 is a Phase 1 study that was terminated before completion, run by Ascenta Therapeutics. The registered enrollment target is 13 participants.
The verdict
NCT00561197, a Phase 1 study, was terminated before completion, sponsored by Ascenta Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
This is a Phase 1/ 2, open-label, single-center study of preoperative chemoradiotherapy and AT-101 in patients with locally advanced esophageal or gastroesophageal junction cancer.
Interventions
- DRUG AT-101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2007-08 |
| Est. Completion | 2010-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00561197
The ClinicalTrials.gov registry entry for NCT00561197 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ascenta Therapeutics, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AT-101 is the first listed.
NCT00561197 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00561197 about?
NCT00561197 is a clinical study titled "An Open-label, Single-center, Phase 1/ 2 Study of Chemoradiotherapy and AT-101 in Patients With Locally Advanced Esophageal or Gastroesophageal Junction Cancer". This is a Phase 1/ 2, open-label, single-center study of preoperative chemoradiotherapy and AT-101 in patients with locally advanced esophageal or gastroesophageal junction cancer.
What is the current status of trial NCT00561197?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2007-08. Estimated completion is 2010-09.
What interventions are being tested in trial NCT00561197?
The interventions under investigation include: AT-101 (DRUG).
Who is sponsoring clinical trial NCT00561197?
This trial is sponsored by Ascenta Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.